VACCINE COMPOSITIONS

Abstract: Novel DNA constructs are provided that are capable of transforming microorganisms such that they can be used as live or attenuated vaccines which induce such immune response at mucosal surfaces. Further provided are such transformed microorganisms per se and vaccine compositions containing them. Preferred constructs of the invention are capable of transforming microorganisms such that they express Y. pestis protein or a protective epitopic fragment thereof while retaining a capability to establish themselves in human or animal gut environment. Several constructs have been identified that are capable of transforming gut dwelling organisms such as S. typhimurium or S. typhi to enable V-protein antigen production.

Description: VACCINE COMPOSITIONS. The present invention relates to novel vaccines for provision of protection against infection with the organism Yersinia pestis and to compositions containing them. Particularly provided are parenterally and orally active vaccines capable of offering protection against bubonic and pneumonic plague, particularly by induction of mucosal immunity in both humans and other animals. Yersinia pestis is the highly virulent causative organism of plague in a wide range of animals, including man. Infection with such organisms results in a high rate of mortality. Studies have shown that the high virulence is due to a complex array of factors encoded by both the chromosome and three plasmids, including the Lcr genes (see Straley, 1991). a fibrinolysin (Sodeinde & Goguen, 1988) , and a capsule. Man is an occasional host in the natural cycle of the disease, and bubonic plague, characteried by the swelling of local lymph nodes, may occur following the bite of an infected flea. One of the complications of bubonic plague is secondary pneumonia, and in such cases the disease is readily transmitted between humans by airborne droplets. Plague is endemic in regions of North and South America, Africa, China and Asia (see Butler (1983) 'Plague and Other Yersinia Infections'; Plenum Press, New York). Current outbreaks are believed to be part of the fourth world pandemic of the disease, and thus there is a clear need to protect individuals living or travelling inn endemic areas, and laboratory workers handling the bacterium. The current whole cell vaccines available for prevention of plague are highly heterogenous, resulting in side effects which make them unsuitable for widespread use (Reisman, (1970); Meyer et al (197*0; Marshall et al (197*0). One current vaccine for plague is the Cutter vaccine, comprising formaldehyde killed plague bacilli, which is administered to the body by intramuscular injection. However, parenteral immunisation, although effective in inducing systemic immunity, does not effectively induce mucosal immunity (McGhee et al, (1992) Vaccine 1Q., 75 _ 88) . So far no vaccine capable of producing a protective immune response at mucosal surfaces has been reported. The live attenuated vaccine (Meyer et al ibid) EV76 was tested extensively and used in the former Soviet Union from 1939. although its efficacy in evoking an immune response in man is questionable (Meyer et al (1970 J- Infect. Dis. 129 Supp: 13-18) . It has been shown that the virulence of EV76 differs in several animal species, and non-human primates are particularly susceptible to a chronic infection with this strain. In the Western World the vaccine is considered to be unsuitable for mass vaccinations due to the extreme severity of the side effects and the possibility of the strain reverting to full virulence. One of several known Y.pestis antigens is the Y. pestis LcrV (V antigen), an unstable 37-3 kDa monomeric peptide encoded on the ca. 70 kb Lcr plasmid of ∑_ pestis, _ pseudotuberculosis and _{___ enterocolitica. This plasmid mediates the growth restriction of the organism at 37°C in the presence of less than 2.5mM Ca 2+ . Under such conditions the cells fail to synthesise bulk vegetative proteins although a series of stress proteins and virulence factors are expressed; this response being known as the 'low calcium response' . A non-polar mutation of the lcrV gene has been shown to cause loss of the requirement for Ca + and results in avirulence (Price et al (1991) J. Bacteriol 173. PP 2649-2657). thus V antigen is postulated to act as a virulence factor. Rabbit antiserum rasied against partially purified V antigen has been shown to provide passive protection in mice later challenged intraperitoneally with 100 LD 0 Y. pestis (se Lawton et al (1963) J- Immunol 91. PP 179-184). That it might be a virulence factor was confirmed when monospecific antisera raised against Y. pestis V antigen were shown to protect passively against a parenteral challenge with the bacterium (see Une and Brubaker (1984) J. Immunol. 133 PP 2226-2230) and that antibodies raised to a fusion protein of a V-fragment with Protein A provided passive immunity (Une et al (1987) Contrib. Microbiol. Immunol. 9, I79-I85) . Recently it was demonstrated that polyclonal antisera raised against recombinant V antigen or a protein A/V or antigen fusion (PAV) were also partially protective against Y.pestis KIM (see Motin et al (1994) Infect. Immun. 62. pp4l92-4201) . By absorbing the antisera with truncates of PAV, it was deduced that at least one protective epitope lay between amino acids 168 and 275 of V antigen. The role of V-antigen in virulence is unknown, but Nakajima and Brubaker (1993) Infect. Immun. 61, p23~31 suggested that it may be immunosuppressive, possibly by inhibiting cytokine synthesis, and so prevent the infiltration of host inflammatory cells into infected organs (Une et al (1987) Contrib. Microbiol. Immunol. 9. pl79 _ lδ5; Straley and Cibull (1989) Infect. Immun. 57, pl200-1210) . The passive protection conferred by anti-V antigen serum may therefore be attributed to the neutralisation of this immunosuppressive activity (Nakajima and Brubaker (1993) above). Despite some 30 years having elapsed since the first evidence of its possible implication in Y. pestis virulence there has been no report of use a V antigen based vaccine, whether suitable for oral or parenteral administration or for the purpose of providing mucosal immunity. The present inventors have now provided recombinant DNA constructs that when incorporated into the DNA of microorganisms, particularly of a human or animal gut colonising microorganism, are capable of transforming it such that it is enabled to express a peptide derived from V antigen, or the V antigen itself, which produces a protective immune response against Yersinia pestis in the human or animal body when the microorganism is administered by oral or parenteral routes. Preferably the present invention provides such DNA constructs that transform such a microorganism while allowing it maintaining its ability to colonise the human or animal gut and systemically invade the body. Further provided are plasmids containing these constructs that are capable of transforming a human or animal gut colonising microorganism such that it is enabled to express a protein which produces a protective immune response against Yersinia pestis in a human or animal body when the microorganism is administered by oral or parenteral routes, and again these preferably allow the microorganism to maintain its ability to colonise the human or animal gut and systemically invade the body. Still further provided are human or animal gut colonising microorganism transformed with recombinant DNA or a plasmid containing recombinant DNA according to the invention such that it is enabled to express a protein which produces a protective immune response against Yersinia pestis in a human or animal body when the microorganism is administered by oral or parenteral routes, and preferably capable of maintaining its ability to colonise the human or animal gut. Protective response preferably includes such at mucosal surfaces. A particularly preferred recombinant DNA, plasmid or human or animal gut colonising organism encodes for or expresses all or a protective epitopic part of the mature V protein of Yersinia pestis. A particularly preferred recombinant DNA comprises a DNA sequence as described in SEQ ID No 1 or SEQ ID No 3. more preferably positioned in frame with a promoter such as lacz or nirβ, and preferably in a vector capable of expression and replication in a Salmonella. The preferred constructs of the invention allow production of microorganisms that when orally administered induce local stimulation of the gut-associated lymphoid tissue (GALT) and, by trafficking of lymphocytes through the common mucosal immune system provide a secondary stimulation of bronchial associated lymphoid tissue (BALT) thus providing secretory IgA response at respiratory mucosal surfaces. The microorganisms provided by transformation using the DNA of the invention, in vector or directly inserted format, are preferably attenuated, more preferably attenuated salmonella. Attenuated microorganisms such as S. typhimurium have been well characterised as carriers for various heterologous antigens (Curtiss, (1990); Cardenas and Clements, (1992)). Attenuation may be effected in a number of ways, such as by use of the aro A and/or aro C mutation approach (see Hosieth et al (1981) Nature 291. 238-239; Dougan et al (1986) Parasite Immunol 9, 151-160; Chatfield et al (1989) Vaccine 7. 495-498) ; multiple mutations such as aro A and aro C mutants as described by Hone et al (1991) Vaccine 9. PP 810-816 may also be used. However any suitably defective organism that is safe for intended use may be employed. Many other such attenuated deletions and mutations will be known for these and other microorganisms which will render them suitable for transformation with constructs of the present invention for the purposes of expressing vaccine proteins in the gut and/or gut colonisation in animals to be treated for Y.pestis. For human vaccination vectors containing the constructs of the present invention are placed in attenuated S. tvphi and that transformed organism used as active agent for a live oral vaccine. When the DNA of the invention is used to transform the attenuated microorganism by direct insertion into its DNA this may be by direct integration into a gene. Alternatively when incorporated in the form of a plasmid that expresses V protein or an epitopic fragment thereof this may be such that only the V protein or fragment is expressed or that this is expressed as a fusion peptide with a further protein or peptide fragment. Such further protein or peptide fragment might be such as to promote export of mature protein or peptide through the cell membrane or might be a further Y. pestis antigen. The lcr gene was cloned from Y. pestis strain KIM by Price et al and its nucleotide sequence published in J. Bacteriol (1989) 171. PP 5646-5653- In the examples below this information was used to design oligonucleotide primers which could amplify the gene from Y. pestis (strain GB) using the polymerase chain reaction (PCR) . PCR primers were designed to be complementary to respective sequences flanking the 5' and 3' ends of the IcrV gene but also having 5' end tails including a restriction enzyme recognition site to enable cloning of amplified IcrV gene directionally into a plasmid vector (the 5' primer including an EcoRI site and the 3' primer containing a SacI site). In the examples below the constructs of the invention include a lac promoter, but other promoters such as the macrophage promoter (nirβ) may be used. The method, constructs, microorganisms and vaccines of the invention will now be exemplified by way of illustration only by reference to the following Sequence listing, Figure and Examples. Still further embodiments will be evident to those skilled in the art in the light of these. SEQUENCE LISTING: SEQ ID No 1: Shows the nucleotide and derived amino acid sequence of a DNA of the invention with the last 6 bases of vector pMAL-p2 or pMAL-c2 into which it is cloned at the 5' end using the EcoRI site in sequence GAATTC (derived from the 5' end PCR primer) and at the 3' end at the Sail site in sequence GTCGAC (derived from the 3' end PCR primer) . The base at position 1006 has been altered by SDM to a T to create a second in frame stop codon. The start of the sequence is a factor Xa cleavage site. SEQ ID No 2: Shows the amino acid sequence of the peptide expressed by the DNA of the invention, with two amino acids encoded for by the vector (I and S) at the N-terminal end. SEQ ID No 3: Shows the nucleotide and derived amino acid sequence of a second DNA of the invention with the last 10 bases of a vector pGEX~5X-2 into which it is cloned shown at the 5' end using the EcoRI site in sequence GAATTC (GA derived from the 5' end PCR primer) and the Sail site in sequence GTCGAC (GTCGAC derived from the 3' end PCR primer) . The base at position 1006 has been altered by SDM to create a second in frame stop codon; the base at position 16 has been altered to a C from an A to create the EcoRI site. The start of the sequence is a factor Xa cleavage site. SEQ ID No 4: Shows the amino acid sequence of the peptide expressed by the second DNA of the invention, with four amino acids encoded by the vector (G, I, P and G) at the N-terminal end. EXAMPLES. Manipulation of DNA. Chromosomal DNA was isolated from Y. pestis by the method of Marmur. The gene encoding V-antigen (IcrV) was amplified from Y.pestis DNA using the polymerase chain reaction (PCR) with 125pmol of primers homologous to sequences from the 5' and 3' ends of the gene (see Price et al (1989) J. Bacteriol 171 P5646-5653). The sequences of the 5' primer (V/5'E: GATCGAATTCATTAGAGCCTACGAACAA) and the 3' primer (GGATCGTCGACTTACATAATTACCTCGTGTCA) also included 5' regions encoding the restriction sites EcoRI and Sail, respectively. In addition, one nucleotide (*) was altered from the published sequence of IcrV (Price et al, 198 ). so that the amplified gene encoded an extra termination codon (TAA) . The PCR primers were prepared with a DNA synthesiser (392 Applied Biosystems) . A DNA fragment was obtained after 30 cycles of amplification (95°C, 20secs, 45°C, 20secs, 72°C,. 30 sees; Perkin 9600 GeneAmp PCR System). The fragment was purified, digested with EcoRI and Sail, ligated with suitably digested plasmid pGEX-5X-2 Amplified IcrV gene was cloned into three different plasmid vectors: EXAMPLE 1: pMAL-p2: a vector designed to express the cloned gene as a fusion product with a maltose binding protein (MBP) . The C-terminus of the MBP is fused to the N-terminus of the V-antigen. The fusion protein so produced on expression is exported to the periplasm. Vector including the V-antigen DNA sequence was designated pVMPlOO. EXAMPLE 2: pMAL-c2: a vector similar to pMAL-p2 except that MBP-V antigen fusion protein is expressed cytoplasmically. The recombinant plasmid was designated pVMClOO. EXAMPLE : pGEX~5X-2: a vector designed to express the cloned gene as a fusion protein with glutathione-S-transferase (GST) . The C-terminus of GST is fused to the N-terminus of V antigen and the fusion protein is expressed cytoplasmically. The recombinant plasmid was designated PVG100. All the vectors contain the P tac promoter and the lacI Q gene; the latter encoding the lac repressor which turns off transcription from P tac in Escherichia coli until IPTG is added. The plasmids contain the origin of replication from pBR322 and as a result replicate to a low copy number in the bacterial cell. Each of the recombinant plasmids were electroporated into Salmonella typhimurium strain SL3261, an attenuated strain that has been used extensively as a live vaccine vector for the expression of foreign antigens. It contains a specific deletion mutation in the aroA gene which makes the mutant dependent upon certain aromatics for growth (see Hosieth et al). For producing microorganism suitable for human vaccination use electroporation is into attenuated Salmonella typhi. The recombinant plasmids all expressed V antigen as shown by Western blotting of S. typhimurium cultures and probing with a monospecific anti-V antigen polyclonal antiserum supplied by R Brubaker, Dept Microbiology, Michigan State University, East Lansing, MI 48824-1101, USA. Recombinant S. typhimurium were innoculated intravenously into mice at 5 x 10 7 cfu/dose and shown to colonise the liver and spleen at high levels; between 8 x 10 6 and 10 8 cfu per organ were recovered. The majority of the bacterial cells recovered were also ampicillin resistant indicating retention of recombinant plasmids. SEQUENCE LISTING (1 GENERAL INFORMATION: (i APPLICANT: (A NAME: THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY (B STREET: WHITEHALL (C CITY: LONDON (E COUNTRY: UNITED KINGDOM (GB) (F POSTAL CODE (ZIP): SW1A 2HB (A NAME: RICHARD WILLIAM TITBALL (B STREET: DMD CBDE PORTON DOWN (C CITY: SALISBURY (D STATE: WILTSHIRE (E COUNTRY: UNITED KINGDOM (GB) (F POSTAL CODE (ZIP): SP4 OJQ (A NAME: EDITH DIANE WILLIAMSON (B STREET: DMD CBDE PORTON DOWN (C CITY: SALISBURY (D STATE: WILTSHIRE (E COUNTRY: UNITED KINGDOM (GB) (F POSTAL CODE (ZIP): SP4 OJQ (A NAME: SOPHIE E C LEARY (B STREET: DMD CBDE PORTON DOWN (C CITY: SALISBURY (D STATE: WILTSHIRE (E COUNTRY: UNITED KINGDOM (GB) (F POSTAL CODE (ZIP): SP4 OJQ (ii) TITLE OF INVENTION: VACCINES (iii) NUMBER OF SEQUENCES: 4 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: C-DOS/MS-DOS (D) SOFTWARE: Patentin Release @1.0, Version @1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1014 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Yersinia pestis (ix) FEATURE (A) NAME/KEY CDS (B) LOCATION 1..987 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATT TCA GAA TTC ATT AGA GCC TAC GAA CAA AAC CCA CAA CAT TTT ATT 48 lie Ser Glu Phe lie Arg Ala Tyr Glu Gin Asn Pro Gin His Phe lie 1 5 10 15 GAG GAT CTA GAA AAA GTT AGG GTG GAA CAA CTT ACT GGT CAT GGT TCT 96 Glu Asp Leu Glu Lys Val Arg Val Glu Gin Leu Thr Gly His Gly Ser 20 25 30 TCA GTT TTA GAA GAA TTG GTT CAG TTA GTC AAA GAT AAA AAT ATA GAT 144 Ser Val Leu Glu Glu Leu Val Gin Leu Val Lys Asp Lys Asn lie Asp 35 40 45 ATT TCC ATT AAA TAT GAT CCC AGA AAA GAT TCG GAG GTT TTT GCC AAT 192 lie Ser lie Lys Tyr Asp Pro Arg Lys Asp Ser Glu Val Phe Ala Asn 50 55 60 AGA GTA ATT ACT GAT GAT ATC GAA TTG CTC AAG AAA ATC CTA GCT TAT 240 Arg Val lie Thr Asp Asp lie Glu Leu Leu Lys Lys lie Leu Ala Tyr 65 70 75 80 TTT CTA CCC GAG GAT GCC ATT CTT AAA GGC GGT CAT TAT GAC AAC CAA 288 Phe Leu Pro Glu Asp Ala lie Leu Lys Gly Gly His Tyr Asp Asn Gin 85 90 95 CTG CAA AAT GGC ATC AAG CGA GTA AAA GAG TTC CTT GAA TCA TCG CCG 336 Leu Gin Asn Gly lie Lys Arg Val Lys Glu Phe Leu Glu Ser Ser Pro 100 105 no AAT ACA CAA TGG GAA TTG CGG GCG TTC ATG GCA GTA ATG CAT TTC TCT 384 Asn Thr Gin Trp Glu Leu Arg Ala Phe Met Ala Val Met His Phe Ser 115 120 125 TTA ACC GCC GAT CGT ATC GAT GAT GAT ATT TTG AAA GTG ATT GTT GAT 432 Leu Thr Ala Asp Arg lie Asp Asp Asp lie Leu Lys Val lie Val Asp 130 135 140 TCA ATG AAT CAT CAT GGT GAT GCC CGT AGC AAG TTG CGT GAA GAA TTA 480 Ser Met Asn His His Gly Asp Ala Arg Ser Lys Leu Arg Glu Glu Leu 145 150 155 160 GCT GAG CTT ACC GCC GAA TTA AAG ATT TAT TCA GTT ATT CAA GCC GAA 528 Ala Glu Leu Thr Ala Glu Leu Lys lie Tyr Ser Val lie Gin Ala Glu 165 170 175 ATT AAT AAG CAT CTG TCT AGT AGT GGC ACC ATA AAT ATC CAT GAT AAA 576 lie Asn Lys His Leu Ser Ser Ser Gly Thr lie Asn lie His Asp Lys 180 185 190 TCC ATT AAT CTC ATG GAT AAA AAT TTA TAT GGT TAT ACA GAT GAA GAG 624 Ser lie Asn Leu Met Asp Lys Asn Leu Tyr Gly Tyr Thr Asp Glu Glu 195 200 205 ATT TTT AAA GCC AGC GCA GAG TAC AAA ATT CTC GAG AAA ATG CCT CAA 672 lie Phe Lys Ala Ser Ala Glu Tyr Lys lie Leu Glu Lys Met Pro Gin 210 215 220 ACC ACC ATT CAG GTG GAT GGG AGC GAG AAA AAA ATA GTC TCG ATA AAG 720 Thr Thr lie Gin Val Asp Gly Ser Glu Lys Lys lie Val Ser lie Lys 225 230 235 240 GAC TTT CTT GGA AGT GAG AAT AAA AGA ACC GGG GCG TTG GGT AAT CTG 768 Asp Phe Leu Gly Ser Glu Asn Lys Arg Thr Gly Ala Leu Gly Asn Leu 245 250 255 AAA AAC TCA TAC TCT TAT AAT AAA GAT AAT AAT GAA TTA TCT CAC TTT 8l6 Lys Asn Ser Tyr Ser Tyr Asn Lys Asp Asn Asn Glu Leu Ser His Phe 260 265 270 GCC ACC ACC TGC TCG GAT AAG TCC AGG CCG CTC AAC GAC TTG GTT AGC 864 Ala Thr Thr Cys Ser Asp Lys Ser Arg Pro Leu Asn Asp Leu Val Ser 275 280 285 CAA AAA ACA ACT CAG CTG TCT GAT ATT ACA TCA CGT TTT AAT TCA GCT 912 Gin Lys Thr Thr Gin Leu Ser Asp lie Thr Ser Arg Phe Asn Ser Ala 290 295 300 ATT GAA GCA CTG AAC CGT TTC ATT CAG AAA TAT GAT TCA GTG ATG CAA 960 lie Glu Ala Leu Asn Arg Phe lie Gin Lys Tyr Asp Ser Val Met Gin 305 310 315 320 CGT CTG CTA GAT GAC ACG TCT GGT AAA TGACACGAGG TAATTATGTA 1007 Arg Leu Leu Asp Asp Thr Ser Gly Lys 325 AGTCGAC 1014 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: lie Ser Glu Phe lie Arg Ala Tyr Glu Gin Asn Pro Gin His Phe lie 1 5 10 15 Glu Asp Leu Glu Lys Val Arg Val Glu Gin Leu Thr Gly His Gly Ser 20 25 30 Ser Val Leu Glu Glu Leu Val Gin Leu Val Lys Asp Lys Asn lie Asp 35 40 4 lie Ser lie Lys Tyr Asp Pro Arg Lys Asp Ser Glu Val Phe Ala Asn 50 55 60 Arg Val lie Thr Asp Asp lie Glu Leu Leu Lys Lys lie Leu Ala Tyr 65 70 75 80 Phe Leu Pro Glu Asp Ala lie Leu Lys Gly Gly His Tyr Asp Asn Gin 85 90 95 Leu Gin Asn Gly lie Lys Arg Val Lys Glu Phe Leu Glu Ser Ser Pro 100 105 no Asn Thr Gin Trp Glu Leu Arg Ala Phe Met Ala Val Met His Phe Ser 115 1 0 125 Leu Thr Ala Asp Arg lie Asp Asp Asp lie Leu Lys Val lie Val Asp 130 135 140 Ser Met Asn His His Gly Asp Ala Arg Ser Lys Leu Arg Glu Glu Leu 145 150 155 160 Ala Glu Leu Thr Ala Glu Leu Lys lie Tyr Ser Val lie Gin Ala Glu 165 170 175 lie Asn Lys His Leu Ser Ser Ser Gly Thr lie Asn lie His Asp Lys 180 185 190 Ser lie Asn Leu Met Asp Lys Asn Leu Tyr Gly Tyr Thr Asp Glu Glu 195 200 205 He Phe Lys Ala Ser Ala Glu Tyr Lys He Leu Glu Lys Met Pro G!n 210 215 220 Thr Thr He Gin Val Asp Gly Ser Glu Lys Lys He Val Ser He Lys 225 230 235 240 Asp Phe Leu Gly Ser Glu Asn Lys Arg Thr Gly Ala Leu Gly Asn Leu 245 2 0 255 Lys Asn Ser Tyr Ser Tyr Asn Lys Asp Asn Asn Glu Leu Ser His Phe 260 265 270 Ala Thr Thr Cys Ser Asp Lys Ser Arg Pro Leu Asn Asp Leu Val Ser 275 280 285 Gin Lys Thr Thr Gin Leu Ser Asp He Thr Ser Arg Phe Asn Ser Ala 290 295 300 He Glu Ala Leu Asn Arg Phe He Gin Lys Tyr Asp Ser Val Met Gin 305 310 315 320 Arg Leu Leu Asp Asp Thr Ser Gly Lys 325 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1014 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Yersinia pestis (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: I..987 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: _ -. GGG ATC CCC GGA ATT CGA GCC TAC GAA CAA AAC CCA CAA CAT TTT ATT 48 Gly He Pro Gly He Arg Ala Tyr Glu Gin Asn Pro Gin His Phe He 1 10 15 GAG GAT CTA GAA AAA GTT AGG GTG GAA CAA CTT ACT GGT CAT GGT TCT 96 Glu Asp Leu Glu Lys Val Arg Val Glu Gin Leu Thr Gly His Gly Ser 20 25 30 TCA GTT TTA GAA GAA TTG GTT CAG TTA GTC AAA GAT AAA AAT ATA GAT 144 Ser Val Leu Glu Glu Leu Val Gin Leu Val Lys Asp Lys Asn He Asp 35 40 5 ATT TCC ATT AAA TAT GAT CCC AGA AAA GAT TCG GAG GTT TTT GCC AAT 192 He Ser He Lys Tyr Asp Pro Arg Lys Asp Ser Glu Val Phe Ala Asn 50 55 60 AGA GTA ATT ACT GAT GAT ATC GAA TTG CTC AAG AAA ATC CTA GCT TAT 240 Arg Val He Thr Asp Asp He Glu Leu Leu Lys Lys He Leu Ala Tyr 65 70 75 80 TTT CTA CCC GAG GAT GCC ATT CTT AAA GGC GGT CAT TAT GAC AAC CAA 288 Phe Leu Pro Glu Asp Ala He Leu Lys Gly Gly His Tyr Asp Asn Gin 85 90 95 CTG CAA AAT GGC ATC AAG CGA GTA AAA GAG TTC CTT GAA TCA TCG CCG 336 Leu Gin Asn Gly He Lys Arg Val Lys Glu Phe Leu Glu Ser Ser Pro 100 105 no AAT ACA CAA TGG GAA TTG CGG GCG TTC ATG GCA GTA ATG CAT TTC TCT 384 Asn Thr Gin Trp Glu Leu Arg Ala Phe Met Ala Val Met His Phe Ser 115 120 125 TTA ACC GCC GAT CGT ATC GAT GAT GAT ATT TTG AAA GTG ATT GTT GAT 432 Leu Thr Ala Asp Arg He Asp Asp Asp He Leu Lys Val He Val Asp 130 135 140 TCA ATG AAT CAT CAT GGT GAT GCC CGT AGC AAG TTG CGT GAA GAA TTA 480 Ser Met Asn His His Gly Asp Ala Arg Ser Lys Leu Arg Glu Glu Leu 145 150 155 160 GCT CAG CTT ACC GCC GAA TTA AAG ATT TAT TCA GTT ATT CAA GCC GAA 8 Ala Glu Leu Thr Ala Glu Leu Lys He Tyr Ser Val He Gin Ala Glu 165 170 175 ATT AAT AAG CAT CTG TCT AGT AGT GGC ACC ATA AAT ATC CAT GAT AAA 576 He Asn Lys His Leu Ser Ser Ser Gly Thr He Asn He His Asp Lys 180 185 190 TCC ATT AAT CTC ATG GAT AAA AAT TTA TAT GGT TAT ACA GAT GAA GAG 624 Ser He Asn Leu Met Asp Lys Asn Leu Tyr Gly Tyr Thr Asp Glu Glu 195 200 205 ATT TTT AAA GCC AGC GCA GAG TAC AAA ATT CTC GAG AAA ATG CCT CAA 672 He Phe Lys Ala Ser Ala Glu Tyr Lys He Leu Glu Lys Met Pro Gin 210 215 220 ACC ACC ATT CAG GTG GAT GGG AGC GAG AAA AAA ATA GTC TCG ATA AAG 720 Thr Thr He Gin Val Asp Gly Ser Glu Lys Lys He Val Ser He Lys 225 230 235 240 GAC TTT CTT GGA AGT GAG AAT AAA AGA ACC GGG GCG TTG GGT AAT CTG 768 Asp Phe Leu Gly Ser Glu Asn Lys Arg Thr Gly Ala Leu Gly Asn Leu 245 250 255 AAA AAC TCA TAC TCT TAT AAT AAA GAT AAT AAT GAA TTA TCT CAC TTT 8l6 Lys Asn Ser Tyr Ser Tyr Asn Lys Asp Asn Asn Glu Leu Ser His Phe 260 265 270 GCC ACC ACC TGC TCG GAT AAG TCC AGG CCG CTC AAC GAC TTG GTT AGC 864 Ala Thr Thr Cys Ser Asp Lys Ser Arg Pro Leu Asn Asp Leu Val Ser 275 280 285 CAA AAA ACA ACT CAG CTG TCT GAT ATT ACA TCA CGT TTT AAT TCA GCT 912 Gin Lys Thr Thr Gin Leu Ser Asp He Thr Ser Arg Phe Asn Ser Ala 290 295 300 ATT GAA GCA CTG AAC CGT TTC ATT CAG AAA TAT GAT TCA GTG ATG CAA 96O He Glu Ala Leu Asn Arg Phe He Gin Lys Tyr Asp Ser Val Met Gin 305 310 315 320 CGT CTG CTA GAT GAC ACG TCT GGT AAA TGACACGAGG TAATTATGTA 1007 Arg Leu Leu Asp Asp Thr Ser Gly Lys 325 AGTCGAC 1014 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Gly He Pro Gly He Arg Ala Tyr Glu Gin Asn Pro Gin His Phe He 1 5 10 15 Glu Asp Leu Glu Lys Val Arg Val Glu Gin Leu Thr Gly His Gly Ser 20 25 30 Ser Val Leu Glu Glu Leu Val Gin Leu Val Lys Asp Lys Asn He Asp 35 40 He Ser He Lys Tyr Asp Pro Arg Lys Asp Ser Glu Val Phe Ala Asn 50 55 60 Arg Val He Thr Asp Asp He Glu Leu Leu Lys Lys He Leu Ala Tyr 65 70 75 80 Phe Leu Pro Glu Asp Ala He Leu Lys Gly Gly His Tyr Asp Asn Gin 85 90 95 Leu Gin Asn Gly He Lys Arg Val Lys Glu Phe Leu Glu Ser Ser Pro 100 105 no Asn Thr Gin Trp Glu Leu Arg Ala Phe Met Ala Val Met His Phe Ser 115 0 125 Leu Thr Ala Asp Arg He Asp Asp Asp He Leu Lys Val He Val Asp 130 135 140 Ser Met Asn His His Gly Asp Ala Arg Ser Lys Leu Arg Glu Glu Leu 145 150 155 160 Ala Glu Leu Thr Ala Glu Leu Lys He Tyr Ser Val He Gin Ala Glu 165 170 175 He Asn Lys His Leu Ser Ser Ser Gly Thr He Asn He His Asp Lys 180 185 190 Ser He Asn Leu Met Asp Lys Asn Leu Tyr Gly Tyr Thr Asp Glu Glu 195 200 205 He Phe Lys Ala Ser Ala Glu Tyr Lys He Leu Glu Lys Met Pro Gin 210 215 220 Thr Thr He Gin Val Asp Gly Ser Glu Lys Lys He Val Ser He Lys 225 230 235 240 Asp Phe Leu Gly Ser Glu Asn Lys Arg Thr Gly Ala Leu Gly Asn Leu 245 250 255 Lys Asn Ser Tyr Ser Tyr Asn Lys Asp Asn Asn Glu Leu Ser His Phe 260 265 270 Ala Thr Thr Cys Ser Asp Lys Ser Arg Pro Leu Asn Asp Leu Val Ser 275 280 285 Gin Lys Thr Thr Gin Leu Ser Asp He Thr Ser Arg Phe Asn Ser Ala 290 295 300 He Glu Ala Leu Asn Arg Phe He Gin Lys Tyr Asp Ser Val Met Gin 305 310 315 320 Arg Leu Leu Asp Asp Thr Ser Gly Lys 325

Claims: CLAIMS . 1. Recombinant DNA that when incorporated into the DNA of a microorganism is capable of transforming that microorganism such that it is enabled to express a peptide or protein which produces a protective immune response against Yersinia pestis in a human or animal body when the microorganism is administered by oral route; wherein the peptide or protein comprises Yersinia pestis V-antigen or a fragment thereof having an epitope capable of evoking a said protective immune response. 2. A plasmid capable of transforming a microorganism such that it is enabled to express a peptide or protein which produces a protective immune response against Yersinia pestis in a human or animal body when the microorganism is administered by oral route characterised in that the plasmid comprises DNA as claimed in claim 1. 3. A microorganism transformed with recombinant DNA or a plasmid containing recombinant DNA such that it is enabled to express a peptide or protein which produces a protective immune response against Yersinia pestis in a human or animal body when administered by oral route characterised in that the recombinant DNA or plasmid are as claimed in claim 1 or 2. 4. A microorganism as claimed in Claim _ characterised in that it is a human or animal gut colonising microorganism. 5. Recombinant DNA, a plasmid or a microorganism as claimed in any one of claims 1 to 4 wherein the transformed microorganism maintains its ability to colonise the human or animal gut and invade the body systemically. 6. Recombinant DNA comprising a DNA sequence as described in SEQ ID No 1 or SEQ ID No 3- 7. A plasmid as claimed in any one of the preceding claims characterised in that it comprises a DNA sequence as described in SEQ ID No 1 or SEQ ID No 3- 8. A plasmid as claimed in Claim 2 or Claim 8 characterised in that it comprises a lac promoter or nirβ promoter in frame with a sequence encoding for all or part of the V antigen. 9. A plasmid as claimed in Claim 9 characterised in that it comprises a pMAL-p2, pMAL-c2 or pGEX~5X-2 vector into which has been inserted a DNA sequence encoding for V-antigen or a fragment thereof having an epitope capable of evoking a protective immune response. 10. A microorganism as claimed in Claim 3 or 4 containing recombinant DNA comprising a DNA sequence as described in SEQ ID No 1 or SEQ ID No 3- 11. A microorganism as claimed in Claim 3 or 4 containing a plasmid as claimed in any one of claims 7 to . 12. A microorganism as claimed in Claim 3. 4, 10 or 11 being an attenuated microorganism not capable of causing disease in humans or animals. 13. A microorganism as claimed in Claim 3. 4, 10 or 11 being an Aro A or Aro C mutant. 14. A microorganism as claimed in Claim 12 or 13 being a Salmonella. 15. A microorganism as claimed in Claim 14 being a Salmonella typhimurium or a Salmonella tvnhi. 16. A vaccine comprising an microorganism as claimed in any one of Claim 3. 4 or 11 to 15 together with a pharmaceutically acceptable carrier. 17. A recombinant DNA, plasmid, microorganism or vaccine according to any one of claims 1 to 16 as described in Example 1.

Inventors: LEARY SOPHIE EMMA CLARE, TITBALL RICHARD WILLIAM, WILLIAMSON ETHEL DIANE, LEARY, SOPHIE, EMMA, CLARE, TITBALL, RICHARD, WILLIAM, WILLIAMSON, ETHEL, DIANE
Applicants: LEARY SOPHIE EMMA CLARE, SECR DEFENCE BRIT, TITBALL RICHARD WILLIAM, WILLIAMSON ETHEL DIANE, LEARY, SOPHIE, EMMA, CLARE, THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI, TITBALL, RICHARD, WILLIAM, WILLIAMSON, ETHEL, DIANE
Application year: 1995
Main classification: C12N15
IPC codes: A61K39, A61P31, C07K14, C12N1, C12N15, C12R1